Autobio(SH:603658) Sou Hu Cai Jing·2025-08-20 11:16Core Viewpoint - Antu Biology's stock closed at 41.82 yuan, with a rolling PE ratio of 20.96 times, and a total market capitalization of 23.897 billion yuan, indicating a relatively lower valuation compared to the industry average [1] Company Summary - Antu Biology specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - The company was listed among the "Top 100 Pharmaceutical Companies in China for 2023" and achieved second place in the "Top 100 Pharmaceutical Enterprises R&D Index" due to its outstanding performance in R&D results and support indices [1] Financial Performance - For the first quarter of 2025, Antu Biology reported a revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76% year-on-year, with a gross profit margin of 65.07% [1] - As of the first quarter of 2025, three institutions held shares in Antu Biology, with a total holding of 12.7156 million shares valued at 477 million yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 59.32 times, with a median of 39.97 times, positioning Antu Biology at 43rd place within the industry [1][2] - The industry average market capitalization is 121.09 billion yuan, with the median at 59.06 billion yuan, indicating that Antu Biology operates in a competitive market environment [2]